Palbociclib is the first selective CDK4/6 inhibitor applied in the treatment of breast cancer (26, 27), and it has been reported to enhance radiosensitivity of HPV negative head and neck squamous cell carcinomas by inhibiting CDK4/6 (21). The gene discussed is CDK4; the disease is breast carcinoma.